Do we need this task?

Written 2026-04-21 by Claude (Opus 4.7) at user request. Independent review of whether task-3b13 addresses a real gap and meaningfully de-risks the BSI Round 1 response. Written after the task brief was seeded with a slightly corrupted version of the celine-clinical-consultant and bsi-clinical-auditor agents, so the brief's reasoning is treated as suspect and re-derived from the source documents.

TL;DR

Yes, keep the task — but its load-bearing value is narrower than the CLAUDE.md framing suggests. The real audit-risk payoff is closing a factual-alignment contradiction between the CEP Confirmatory Phase row and the already-completed MAN_2025 evidence base, not satisfying ISO 14155 §6.4 CIP-content-at-CEP-time. Cost ≈ 30–60 minutes. Residual risk if skipped is a foreseeable and avoidable round-2 follow-up finding.

What I verified from the source documents

1. CEP row is stale

R-TF-015-001-Clinical-Evaluation-Plan.mdx, Confirmatory Phase table, MAN_2025 row (line 1201, not line 1156 as stated in the task brief) currently carries:

• State of process: Planned
• Initiation date: Planned
• Inclusion period: Planned. This study will include a minimum of 5 dermatologists to assess 149 images...
• Completion date: Planned
• Date of the study report: Planned

2. MAN_2025 CIP is fully drafted and already contains the three "missing" fields

R-TF-015-004 MAN_2025 instance (.../Investigation/man-2025/r-tf-015-004.mdx, 432 lines):

• §Sample size / §Power calculation (lines 152–166): McNemar paired-binary test, baseline 60%, expected 70%, α = 0.05 two-sided, 1 − β = 0.80, 25% discordant → ≈ 200 paired observations required; floor of 5 readers × 149 images = 745 observations, effective N ≈ 460 at ICC 0.15; sensitivity range ICC 0.05–0.30.
• §Reference standard (ground truth) (lines 136–140): published atlas diagnosis encoded as ICD-11, established prior to and independently of the investigation; limitations (non-histopathology-confirmed) and mitigations (dataset size 149, self-controlled design, methodological consistency with SAN_2024/BI_2024/PH_2024) stated.
• §Duration (line 207): planning phase began October 2025; data collection January–April 2026; database closure 17 April 2026.

3. Every other audit-visible document already reflects the completed state

• CIR R-TF-015-006 MAN_2025 instance — drafted with locked-dataset tables (19 enrolled / 16 primary cohort / 3 screen failures).
• Annex E R-TF-015-010 MAN_2025 instance — drafted.
• CER R-TF-015-003 — MAN_2025 cross-referenced in §Representativeness and §Sufficiency determination.
• BSI Item 3b response — cites MAN_2025 as complete.
• Upstream completed-tasks/task-3b4-mrmc-dark-phototypes/CLAUDE.md — status "Complete" with four-way adequacy review applied 2026-04-20.

What the CLAUDE.md brief gets wrong

The task brief frames the missing content as a completeness issue: "ISO 14155:2020 §6.4 and MDR Annex XV require for a planned investigation at CEP time: sample-size rationale, reference standard, and committed timeline."

That framing is weak because:

1. ISO 14155 §6.4 is CIP-content scope, not CEP-content scope. The CIP itself is audit-visible at R-TF-015-004 and already carries those fields in full. MEDDEV 2.7/1 Rev 4 Annex A3 and MDCG 2020-13 Section E ask the CEP to summarise planned investigations and cross-reference to the CIP — they do not require the CEP to replicate the power calc.
2. The study is no longer "planned". Data-lock was 17 April 2026. A "Planned" state in the CEP for a data-locked investigation is not an ISO 14155 §6.4 gap; it is a factual-accuracy gap.
3. Erin-voice rationale is speculative. The brief says "Erin will ask for power / alpha / effect size assumptions at the CEP row." Erin could just as easily follow the CEP's explicit cross-reference to R-TF-015-003 per-study appraisal and R-TF-015-004 CIP, which is the normal regulatory reading order.

Why the task is still worth doing (the real audit-risk target)

The load-bearing reason is internal contradiction between the CEP and the rest of the evidence base. A reviewer reading top-down (CEP → CER → CIP / CIR) sees:

Document	MAN_2025 state
CEP Confirmatory Phase row	Planned (5 fields)
CER §Representativeness / §Sufficiency	Completed, cross-referenced
CIP R-TF-015-004	Completed, data-lock 17 April 2026
CIR R-TF-015-006	Drafted, 16 primary-cohort readers, locked-dataset tables
Annex E R-TF-015-010	Drafted
BSI Item 3b response	Complete → phototype gap closed

This is the class of inconsistency that experienced clinical reviewers — including Erin, who reads CEP top-down — flag inside the first 30 seconds of the evaluation. The round-2 question writes itself: "You state MAN_2025 is complete and closes the phototype gap, but your CEP shows it as Planned. Which is correct?"

The risk is not that the evidence is wrong. The risk is that the planning document visibly lags the reality, which is a foreseeable and cheap-to-prevent finding.

Cost-benefit

• Fix cost: 30–60 minutes. Pure pull-through from an already-drafted, already-reviewed CIP into a single CEP row.
• Audit-risk payoff: moderate. Closes one clean, obvious inconsistency that an experienced reviewer would almost certainly raise. Not catastrophic if skipped — the CIP/CIR/CER carry the real evidence — but a round-2 item that costs nothing to prevent.
• Risk of doing the task: very low. The main hazard is accidentally shifting MAN_2025 off Pillar 3 §4.4 Rank 11 framing, which is already flagged in the CLAUDE.md "What NOT to do" section.

Recommended reframing of the CLAUDE.md goal

Swap the primary rationale from:

"CIP-level content (sample-size rationale, reference standard, committed timeline) must appear in the CEP row per ISO 14155 §6.4 / MDR Annex XV for a planned investigation."

To:

"The CEP Confirmatory Phase row for MAN_2025 must be brought into factual alignment with the completed CIP, CIR and CER. MAN_2025 is no longer a planned investigation — data-lock was 17 April 2026 — and the CEP row must reflect that state to avoid an obvious cross-document contradiction with the BSI Item 3b response."

Recommended scope (minimum sufficient)

1. Required — replace the five Planned strings with the actual values:
   • State of process: Completed
   • Initiation date: October 2025 (planning phase) or January 2026 (data-collection start) — align to the convention used for the other completed rows in the same table.
   • Inclusion period: January 2026 to April 2026
   • Completion date: 17 April 2026 (data-lock)
   • Date of the study report: [per CIR]
2. Recommended — add a one-sentence sample-size summary pointing to R-TF-015-004 §Sample size (e.g. "Sample size determined by a McNemar paired-binary power calculation powered at 0.80 against a +10 pp primary endpoint; full derivation in R-TF-015-004 §Sample size.").
3. Recommended — add a one-sentence reference-standard summary pointing to R-TF-015-004 §Reference standard (ground truth) (e.g. "Reference standard: published atlas diagnosis encoded as ICD-11, established independently of the investigation; see R-TF-015-004 §Reference standard.").
4. Do NOT duplicate the full power calc into the CEP — the CEP is a summary document; the full derivation lives in the CIP.
5. Do NOT shift MAN_2025 off Pillar 3 §4.4 Rank 11 framing.

Verdict

Task-3b13 is a real, audit-visible, cheap-to-close inconsistency that should be fixed before the Round 1 response is submitted. Keep the task. Re-frame its primary goal from "ISO 14155 §6.4 completeness" to "CEP ↔ CIP/CIR/CER factual alignment." Treat it as a 30–60 minute editorial pull-through rather than a new analytical pass. Skipping it is a modest but foreseeable round-2 risk; doing it costs almost nothing.